Navigation Links
NIAID describes research priorities to fight drug-resistant tuberculosis
Date:4/22/2008

Tuberculosis (TB) has long been one of the worlds great killers. Now, forms of drug-resistant TB--multidrug (MDR) and extensively drug-resistant (XDR)--are occurring at an ominous and accelerating rate. To help in the fight against drug-resistant TB, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has formulated an MDR and XDR TB research agenda.

A summary of the agenda, authored by NIAID Director Anthony S. Fauci, M.D., and members of the NIAID Tuberculosis Working Group, is now available online in The Journal of Infectious Diseases.

The TB diagnostic tools in use today are antiquated, slow and insensitive; TB drug regimens are complex and lengthy; and the only vaccine available does not provide effective protection against adult pulmonary TB, says Dr. Fauci. The challenge of TB control is further compounded by the rise of drug-resistant TB, and we anticipate that the NIAID Research Agenda for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis will contribute substantively to the fight against this emerging threat.

The World Health Organization (WHO) estimates that 500,000 people worldwide have MDR TB, while the frequently fatal XDR TB has been detected in 46 countries. Factors contributing to the rising tide of drug-resistant TB include

  • Lack of routine testing to determine TB drug-sensitivity
  • Incomplete treatment of people infected with TB-causing bacteria
  • The epidemic of TB in HIV-infected people
  • Limited TB research by pharmaceutical companies, resulting in few new anti-TB drugs or other interventions

The NIAID research agenda complements domestic and international efforts to prevent and control the spread of MDR and XDR TB. Whereas the WHOs STOP TB Partnership plan emphasizes increased surveillance and control and treatment efforts, the NIAID agenda focuses on biomedical research. The Institute also collaborates with the Centers for Disease Control and Prevention and other NIH Institutes and Centers on TB research efforts in the United States.

To prevent the further emergence and spread of MDR and XDR TB, the NIAID agenda identifies areas of biomedical research that are likely to contribute substantially to a global public health response. Building on existing efforts within the international network of TB research, NIAIDs priorities include efforts to

  • Develop and test reliable technologies to rapidly diagnose TB and to identify drug resistance
  • Define the most effective use of existing TB therapies and other antibiotics available to treat drug-resistant TB and develop new drugs, particularly to treat MDR and XDR TB
  • Better understand the basic biology of TB-causing bacteria and their interaction with the human host that underlie the development of drug-resistant TB
  • Understand the epidemiology of drug-resistant TB
  • Investigate the various manifestations of TB in adults, children and those with co-infections, including HIV/AIDS
  • Conduct research to develop new vaccines and other preventive strategies

NIAID is leading and sponsoring research activities to create a foundation of knowledge for the discovery of new diagnostics, drugs and vaccines. The Institute also supports the efforts of organizations, such as drug companies and public-private partnerships, to further develop these products into tools and approaches that enhance the quality of care for people with TB.

Only a concerted global effort can counteract the rise of drug-resistant TB, notes Dr. Fauci. Development of improved diagnostics and better treatment and control strategies will depend on collaboration with our partners at every research step, from basic science to large clinical trials.


'/>"/>

Contact: NIAID News Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID funds $51M contract to create comprehensive model of immune responses
2. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
3. NIAID scientists identify new cellular receptor for HIV
4. NIAID to convene HIV Vaccine Summit
5. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
6. Study Describes Molecules That Control Blood Pressure
7. Bionovo Describes a New Class of Therapeutic Compounds
8. China Bionanometer Industries (CBIU) Describes their Current Production Capacity and Product Lines
9. Stanford researchers find culprit in aging muscles that heal poorly
10. Children of depressed moms do better when dad is involved, SLU researcher finds
11. UCLA researchers identify markers that may predict diabetes in still-healthy people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... GrekTek LLC, ( http://www.grektek.com ) an ... http://kck.st/2g3a1so ) for the HealthyWatch, a new device to help patients manage their ... watch while sharing these events with caregivers in real time. , ...
(Date:12/6/2016)... ... December 06, 2016 , ... Keeping Gift Season Safe, In a season stacked ... and age-appropriate for their recipients. This is the idea behind Safe Toys and Gifts ... items that would make good gifts for children. For companies that produce goods that ...
(Date:12/6/2016)... Overland Park, KS (PRWEB) , ... December 06, 2016 , ... ... online retailers of Mobility Scooters . , Mobility Scooters give freedom to people ... and balance problems. Still others may be facing a long period of rehabilitation after ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) was ... for their industry leading training methods that engage their associates and link their ... global elite in employer-sponsored training and development programs. , “The 2017 Training Top ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward ... to announce the arrival of the newest Sciton laser in January 2017. The ... use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... YORK , Dec. 5, 2016  Balloon catheter ... catheter, which is inserted into the femoral artery in ... the arm to treat constricted blood vessels. These products ... due to atherosclerosis – deposition of lipid substances in ... balloon catheter market is projected to expand at a ...
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., a ... data from two Phase I trials evaluating its ... 58th annual meeting of the American Society of ... . The two datasets show encouraging efficacy ... leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), ...
Breaking Medicine Technology: